First Time Loading...

Ovid Therapeutics Inc
NASDAQ:OVID

Watchlist Manager
Ovid Therapeutics Inc Logo
Ovid Therapeutics Inc
NASDAQ:OVID
Watchlist
Price: 3.06 USD -0.33% Market Closed
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

OVID Price Targets Summary
Ovid Therapeutics Inc

Wall Street analysts forecast OVID stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OVID is 7.91 USD with a low forecast of 4.04 USD and a high forecast of 11.55 USD.

OVID Lowest Forecast
Wall Street Target
4.04 USD
32% Upside
OVID Average Forecast
Wall Street Target
7.91 USD
158% Upside
OVID Highest Forecast
Wall Street Target
11.55 USD
277% Upside
Lowest
Price Target
4.04 USD
32% Upside
Average
Price Target
7.91 USD
158% Upside
Highest
Price Target
11.55 USD
277% Upside
Ovid Therapeutics Inc Competitors:
Price Targets
J
600201
Jinyu Bio-Technology Co Ltd
2% Upside
87S
Roivant Sciences Ltd
45% Upside
RXRX
Recursion Pharmaceuticals Inc
50% Upside
BIO
Biotest AG
19% Downside
J
600201
Jinyu Bio-Technology Co Ltd
2% Upside
87S
Roivant Sciences Ltd
45% Upside
RXRX
Recursion Pharmaceuticals Inc
50% Upside
BIO
Biotest AG
19% Downside
ELYM
Eliem Therapeutics Inc
56% Downside
KYMR
Kymera Therapeutics Inc
40% Upside
HARP
Harpoon Therapeutics Inc
8% Upside
9969
InnoCare Pharma Ltd
52% Upside

Revenue
Forecast

Revenue Estimate
Ovid Therapeutics Inc

The compound annual growth rate of Ovid Therapeutics Inc's revenue for the next 3 years is 336%.

N/A
Past Growth
336%
Estimated Growth
Estimates Accuracy
6%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ovid Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ovid Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-17%
Average Miss
What are analyst estimates?

See Also

Summary
OVID intrinsic value, competitors valuation, and company profile.
DCF Valuation
OVID stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OVID stock valuation using valuation multiples.
Wall Street Estimates
OVID price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OVID stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OVID's stock price target?
Price Target
7.91 USD

According to Wall Street analysts, the average 1-year price target for OVID is 7.91 USD with a low forecast of 4.04 USD and a high forecast of 11.55 USD.

What is Ovid Therapeutics Inc's Revenue forecast?
Projected CAGR
336%

The compound annual growth rate of Ovid Therapeutics Inc's revenue for the next 3 years is 336%.

ALPHA SPREAD
Join more than 134,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.